Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09AYQ
|
|||
| Former ID |
DNC003511
|
|||
| Drug Name |
PIRITREXIM
|
|||
| Synonyms |
Piritrexim; 72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 2 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H19N5O2
|
|||
| Canonical SMILES |
CC1=C2C(=NC(=NC2=NC=C1CC3=C(C=CC(=C3)OC)OC)N)N
|
|||
| InChI |
1S/C17H19N5O2/c1-9-11(6-10-7-12(23-2)4-5-13(10)24-3)8-20-16-14(9)15(18)21-17(19)22-16/h4-5,7-8H,6H2,1-3H3,(H4,18,19,20,21,22)
|
|||
| InChIKey |
VJXSSYDSOJBUAV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 72732-56-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
585461, 596153, 5321568, 7889090, 8183612, 12012913, 14801638, 26704486, 34718371, 46506046, 46518330, 50035075, 50293384, 85866344, 93579418, 103165437, 103855306, 104304731, 126420216, 129485784, 134340716, 135029179, 137008239, 143157948, 160966790, 163724435, 172896495, 178103986, 179151032, 198977797, 208012006, 219402188, 223518945, 225249588, 226399387, 241132020
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dihydrofolate reductase (DHFR) | Target Info | Modulator | [3] |
| KEGG Pathway | One carbon pool by folate | |||
| Folate biosynthesis | ||||
| Metabolic pathways | ||||
| Panther Pathway | Tetrahydrofolate biosynthesis | |||
| Formyltetrahydroformate biosynthesis | ||||
| Pathwhiz Pathway | Folate Metabolism | |||
| Pterine Biosynthesis | ||||
| Pathway Interaction Database | E2F transcription factor network | |||
| Reactome | E2F mediated regulation of DNA replication | |||
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | ||||
| Metabolism of folate and pterines | ||||
| G1/S-Specific Transcription | ||||
| WikiPathways | Nucleotide Metabolism | |||
| Trans-sulfuration and one carbon metabolism | ||||
| Retinoblastoma (RB) in Cancer | ||||
| One Carbon Metabolism | ||||
| Metabolism of water-soluble vitamins and cofactors | ||||
| Metabolism of nitric oxide | ||||
| Folate Metabolism | ||||
| Fluoropyrimidine Activity | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7414). | |||
| REF 2 | ClinicalTrials.gov (NCT00002914) Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract. U.S. National Institutes of Health. | |||
| REF 3 | Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling ... Eur J Med Chem. 2004 Dec;39(12):1079-88. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.